Skip to main content
GOSS
NASDAQ Life Sciences

Gossamer Bio Faces Going Concern Doubt After Phase 3 Miss, 48% Workforce Cut, and Massive Option Repricing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.474
Mkt Cap
$109.676M
52W Low
$0.331
52W High
$3.87
52W Position info
43% above low
Off High info
88% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

GOSS sits 43% above its 52-week low of $0.331.

Summary

Gossamer Bio's 10-K discloses a going concern warning, a failed Phase 3 trial for its lead drug, a 48% workforce reduction, and a massive stock option repricing, signaling severe financial and operational challenges.


Key Events · Financing and Capital Events · GOSS

  • Auditor Issues Going Concern Warning

    The independent registered public accounting firm's opinion on the financial statements contains an explanatory paragraph regarding 'substantial doubt' about the company's ability to continue as a going concern.

  • Lead Candidate Misses Primary Endpoint in Phase 3 Trial

    Seralutinib, the company's lead product candidate, failed to meet its primary endpoint in the Phase 3 PROSERA trial for pulmonary arterial hypertension (PAH), with a placebo-adjusted improvement of 13.3 meters in 6MWD (p = 0.0320), missing the prespecified alpha threshold of 0.025.

  • Significant Workforce Reduction Implemented

    The company commenced a workforce reduction of 77 individuals in March 2026, constituting approximately 48% of its total workforce, aimed at reducing operating expenses and preserving cash.

  • Chief Medical Officer Resigns Amid Restructuring

    Dr. Richard Aranda, the Chief Medical Officer, resigned effective April 15, 2026, in connection with the workforce reduction.


Analysis · GOSS · Life Sciences

Gossamer Bio's annual report reveals a company in severe distress, with auditors expressing 'substantial doubt' about its ability to continue as a going concern. This follows the critical failure of its lead candidate, seralutinib, to meet the primary endpoint in the Phase 3 PROSERA trial for pulmonary arterial hypertension (PAH). In response, the company has implemented a drastic 48% workforce reduction and paused enrollment in another key Phase 3 study (SERANATA for PH-ILD) to conserve cash. Further compounding the negative sentiment, the board approved a significant repricing of 48.7 million stock options to the current low market price, effectively re-incentivizing employees at a much lower bar. The company's cash runway is projected only into Q1 2027, necessitating substantial additional financing. The combination of clinical failure, severe cost-cutting, a going concern warning, and dilutive compensation adjustments presents a highly negative outlook for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOSS was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $109.7M. The 52-week trading range was $0.33 to $3.87. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOSS - Latest Insights

GOSS
Nov 10, 2026, 4:49 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.15
Real-time Price: $11.21 info
Change: +$1.06 (+10%) info
Market Cap: $69.054M info
GOSS
Sep 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.19
Real-time Price: $11.21 info
Change: +$0.0221 (+0.20%) info
Market Cap: $69.054M info
GOSS
Sep 23, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $11.21 info
Change: +$0.2146 (+2%) info
Market Cap: $69.054M info
GOSS
Sep 16, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.93
Real-time Price: $11.21 info
Change: +$0.2846 (+3%) info
Market Cap: $69.054M info
GOSS
Sep 11, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $11.21 info
Change: Reverse Stock Split info
Market Cap: $69.054M info